Merck says diabetes drug on par with standard care

	Tweet

Sitagliptin, a diabetes drug awaiting U.S. regulatory approval, lowered blood sugar to levels that were comparable to those obtained with conventional treatment—and also helped patients lose weight, the drug’s developer, Merck & Co., said on Tuesday.

After 1 year of treatment with sitagliptin (Januvia), one of a new class of diabetes drugs called DPP-4 inhibitors, reductions in A1C levels, a common measure of blood sugar control, were the same as reductions seen with glipizide in patients with type 2 diabetes.

Merck also said patients taking Januvia had weight loss, compared with weight gain on glipizide, and had a significantly lower incidence of hypoglycemia (low blood sugar). The study results were presented at the American Diabetes Association scientific meeting in Washington. 

Patients in the group treated with Januvia lost an average of 1.5 kg (3.3 pounds) after 52 weeks, according to Merck. By comparison, patients treated with glipizide gained 1.1 kg (2.4 pounds).

Obesity is the leading cause of type 2 diabetes, and weight loss associated with Januvia is considered a major advantage over some older diabetes drugs that can cause weight gain.

Nearly 21 million people in the United States, or 7 percent of the population, have diabetes, with type 2 diabetes accounting for 90 percent to 95 percent of the cases, according to the American Diabetes Association.

Merck has said it expects the U.S. Food and Drug Administration to decide whether to approve Januvia by mid-October. 

RELATED STORIES:
Phone contact with nurses linked with better outcomes for women with gestational diabetes   Death rate drops among Americans with diabetes -CDC   Correct treatment of common diabetic foot infections can reduce amputations   “Pre-diabetes,” diabetes rising among U.S. teens   Experimental bariatric surgery controls blood sugar in rats with diabetes   53 millions Americans might develop diabetes by 2025   New inflammation hormone link may pave way to study new drugs for type 2 diabetes   Diabetic retinopathy research could reduce screening costs   Liver fat gets a wake-up call that maintains blood sugar levels   Low testosterone levels could raise diabetes risk for men   Prosthetic lets diabetic get a foot up on life   Dealing with Diabetes, One Patient at a Time

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]